News | January 12, 2026
Aragen slashes drug development time with CHOMax platform
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
Vanda strongly disputes the FDA’s reasoning
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
Subscribe To Our Newsletter & Stay Updated
